Baiyunshan Pharmaceutical Gets Supplementary Approvals for Two Drugs

MT Newswires Live

05/12

China's drug regulator granted Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) a supplemental drug approval for its cefuroxime sodium injection and candesartan cilexetil tablets, according to a Tuesday filing with the Shanghai bourse.

The approvals cover supplementary research.

Cefuroxime sodium is indicated for acute respiratory, urinary tract, and other bacterial infections, while

Candesartan cilexetil is indicated for hypertension.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2634521267"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2634521267\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2634521267?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-12 21:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634521267","market":"fut","top_or_hot":-1,"title":"Baiyunshan Pharmaceutical Gets Supplementary Approvals for Two Drugs","media":"MT Newswires Live","content":"<html><body><p> China's drug regulator granted <a href=\"https://laohu8.com/S/GZPHF\">Guangzhou Baiyunshan</a> Pharmaceutical (SHA:600332, HKG:0874) a supplemental drug approval for its cefuroxime sodium injection and candesartan cilexetil tablets, according to a Tuesday filing with the Shanghai bourse.</p><p>The approvals cover supplementary research.</p><p>Cefuroxime sodium is indicated for acute respiratory, urinary tract, and other bacterial infections, while</p><p>Candesartan cilexetil is indicated for hypertension.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baiyunshan Pharmaceutical Gets Supplementary Approvals for Two Drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaiyunshan Pharmaceutical Gets Supplementary Approvals for Two Drugs\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-05-12 21:19</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> China's drug regulator granted <a href=\"https://laohu8.com/S/GZPHF\">Guangzhou Baiyunshan</a> Pharmaceutical (SHA:600332, HKG:0874) a supplemental drug approval for its cefuroxime sodium injection and candesartan cilexetil tablets, according to a Tuesday filing with the Shanghai bourse.</p><p>The approvals cover supplementary research.</p><p>Cefuroxime sodium is indicated for acute respiratory, urinary tract, and other bacterial infections, while</p><p>Candesartan cilexetil is indicated for hypertension.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600332","symbol_name":"白雲山","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2634521267","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2634521267","pubTimestamp":1778591950,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"China's drug regulator granted Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) a supplemental drug approval for its cefuroxime sodium injection and candesartan cilexetil tablets, according ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600332":"白云山","BK0028":"国家队","BK0097":"医药电商","BK1197":"保健护理产品经销商","BK0175":"白马股","BK0183":"MSCI概念","BK0070":"员工持股","BK0188":"融资融券","BK1515":"抗疫概念","BK1521":"挪威政府全球养老基金持仓","BK0239":"医药制造","BK1606":"中医药概念","BK1191":"制药","BK0096":"民营医院","BK0196":"行业龙头","BK0012":"证金概念","00874":"白云山"},"translate_title":"白云山药业两款药品获补充批件","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600332":0.9,"00874":0.9},"content_text":"China's drug regulator granted Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) a supplemental drug approval for its cefuroxime sodium injection and candesartan cilexetil tablets, according to a Tuesday filing with the Shanghai bourse.The approvals cover supplementary research.Cefuroxime sodium is indicated for acute respiratory, urinary tract, and other bacterial infections, whileCandesartan cilexetil is indicated for hypertension.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}